文献速递心力衰竭与心肌病

疑似射血分数保留心衰中NT-proBNP与左室舒张末压不一致对诊断和预后的意义

Discordance between N-terminal pro-B-type natriuretic peptide and left ventricular end-diastolic pressure in suspected heart failure with a preserved ejection fraction: implications for diagnosis and prognosis.
PubMed 文献 · Heart · 2026-09-15

该前瞻性队列纳入514例择期左心导管检查且H2FPEF评分中高概率的疑似HFpEF患者,同步测量NT-proBNP与LVEDP。结果42%患者两者不一致,仅NT-proBNP升高或两者均升高者死亡风险显著增加,而仅LVEDP升高者无显著超额死亡。

要点

  • NT-proBNP与LVEDP在疑似HFpEF中常不一致(42%)。
  • 仅NT-proBNP升高或两者均升高与死亡风险增加相关。
  • 仅LVEDP升高未显示与超额死亡显著相关。

核心结论

  • NT-proBNP与LVEDP常不一致,提供互补的预后信息。
  • 两者均升高时死亡风险最高,仅NT-proBNP升高亦增加死亡风险。
  • 仅LVEDP升高与超额死亡无显著关联。

研究设计与样本

  • 前瞻性全纳入队列(UKSH-Trial注册号AZ-D412-/21),纳入择期左心导管检查成人。
  • 同步测量侵入性LVEDP与NT-proBNP,计算H2FPEF评分。
  • 纳入射血分数≥50%且H2FPEF中高概率者,按指南NT-proBNP阈值和LVEDP≥16 mm Hg分为四组。
  • 主要终点为全因死亡,采用多变量Cox模型调整年龄、性别、肾功能和H2FPEF风险类别。

主要发现

  • 514例参与者平均年龄70岁,女性49%。
  • 四组分布分别为29%、14%、28%、29%,不一致率42%。
  • 临床特征与NT-proBNP的一致性高于LVEDP。
  • 与第1组相比,第3组调整后死亡HR 2.26(95%CI 1.02-5.01),第4组HR 3.33(95%CI 1.54-7.20)。
  • 第2组调整后死亡HR 1.34(95%CI 0.45-4.02),无显著差异。

关键数值与推荐

  • 指南推荐NT-proBNP阈值用于分组。
  • LVEDP≥16 mm Hg定义为升高。
  • H2FPEF评分用于筛选射血分数≥50%的中高概率患者。

临床怎么用

  • 疑似HFpEF应整合生物标志物与血流动力学评估。
  • NT-proBNP升高提示预后不良,需加强风险分层。
  • 仅LVEDP升高者死亡风险未显著增加,解读需谨慎。

局限性

  • 研究为观察性队列,需前瞻性验证。
  • 样本来自择期左心导管检查人群,可能存在选择偏倚。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diagnosing heart failure with preserved ejection fraction (HFpEF) remains challenging, as natriuretic peptides and resting haemodynamic measurements reflect complementary but incomplete aspects of myocardial stress and filling pressure. METHODS: In this prospective all-comer cohort (UKSH-Trial registration number AZ-D412-/21), adults undergoing elective left heart catheterisation underwent simultaneous invasive left ventricular end-diastolic pressure (LVEDP) measurement and N-terminal pro-B-type natriuretic peptide (NT-proBNP) sampling. The H₂FPEF score was calculated in patients with preserved ejection fraction (≥50%), and those with intermediate or high probability were included. Patients were classified using guideline-recommended NT-proBNP thresholds and LVEDP ≥16 mm Hg into four groups: normal (Group 1), isolated LVEDP elevation (Group 2), isolated NT-proBNP elevation (Group 3) and combined elevation (Group 4). The primary endpoint was all-cause mortality, analysed using multivariable Cox models, including age, sex, renal dysfunction and H2FPEF risk category. RESULTS: Among 514 participants (mean age 70 years, 49% women), group distribution was 29%, 14%, 28% and 29%. Discordance was common (42%). Clinical profiles aligned more closely with NT-proBNP than LVEDP. Compared with Group 1, adjusted mortality was not significantly higher in Group 2 (HR 1.34, 95% CI 0.45 to 4.02), whereas it was significantly higher in Group 3 (HR 2.26, 95% CI 1.02 to 5.01) and Group 4 (HR 3.33, 95% CI 1.54 to 7.20). CONCLUSIONS: NT-proBNP and LVEDP are frequently discordant and provide complementary prognostic information in suspected HFpEF. Mortality risk was highest when both were elevated and was also increased with isolated NT-proBNP elevation, whereas isolated LVEDP elevation was not associated with excess mortality. These findings support integrated biomarker-haemodynamic assessment and warrant prospective validation.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Güder, Störk, Frantz, et al. Discordance between N-terminal pro-B-type natriuretic peptide and left ventricular end-diastolic pressure in suspected heart failure with a preserved ejection fraction: implications for diagnosis and prognosis. Heart. 2026. PMID: 42744605. doi:10.1136/heartjnl-2026-328688

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。